AMGN - Amgen Inc.
NEXT EARNINGS:
Apr 29, 2026
EPS Est: $4.80
|
Rev Est: $8.6B
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$347.73
DETAILS
HIGH:
$432.00
LOW:
$185.00
MEDIAN:
$355.00
CONSENSUS:
$347.73
DOWNSIDE:
0.02%
Market Cap:
187.49B
Volume:
9,166,928
Avg Volume:
2,615,376
52 Week Range:
261.43-391.29
Sector:
Healthcare
Industry:
Drug Manufacturers - General
Beta:
0.42
Last Dividend:
$9.66
Exchange:
NASDAQ
Country:
US
Employees:
28,000
IPO Date:
1983-06-17
EPS (TTM):
14.33
P/E Ratio:
22.84
Revenue (TTM):
36.74B
Total Assets:
90.59B
Total Debt:
54.60B
Cash & Equiv:
9.13B
Rev Growth (5Y):
7.6%
EPS Growth (5Y):
2.9%
FCF Growth (5Y):
-3.9%
ROCE:
16.4%
Debt/Equity:
6.31
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-03 | $5.29 | $4.73 | +11.8% | $9.9B | $9.5B | +4.5% |
| 2025-11-04 | $5.64 | $5.02 | +12.4% | $9.6B | $9.0B | +6.6% |
| 2025-08-05 | $6.02 | $5.28 | +14.0% | $9.2B | $8.9B | +2.6% |
| 2025-05-01 | $4.90 | $4.27 | +14.8% | $8.1B | $8.1B | +1.1% |
| 2025-02-04 | $5.31 | $5.04 | +5.4% | $9.1B | $8.9B | +2.3% |
| 2024-10-30 | $5.58 | $5.11 | +9.2% | $8.5B | $8.5B | 0.0% |
| 2024-08-06 | $4.97 | $4.98 | -0.2% | $8.4B | $8.4B | +0.4% |
| 2024-05-02 | $3.96 | $3.88 | +2.1% | $7.4B | $7.5B | 0.0% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 36.74B | 33.42B | 28.19B | 26.32B | 25.98B | 25.42B | 23.36B | 23.75B | 22.85B | 22.99B | 21.66B | 20.06B |
| Net Income | 7.71B | 4.09B | 6.72B | 6.55B | 5.89B | 7.26B | 7.84B | 8.39B | 1.98B | 7.72B | 6.94B | 5.16B |
| EPS | 14.33 | 7.62 | 12.56 | 12.18 | 10.34 | 12.40 | 12.96 | 12.70 | 2.71 | 10.32 | 9.15 | 6.80 |
| Total Assets | 90.59B | 91.84B | 97.15B | 65.12B | 61.16B | 62.95B | 59.71B | 66.42B | 79.95B | 77.63B | 71.58B | 69.01B |
| Total Debt | 54.60B | 60.10B | 64.61B | 38.95B | 33.31B | 32.99B | 29.90B | 33.93B | 35.34B | 34.60B | 31.43B | 30.71B |
| Cash & Equivalents | 9.13B | 11.97B | 10.94B | 7.63B | 7.99B | 6.27B | 6.04B | 6.95B | 3.80B | 3.24B | 4.14B | 3.73B |
| Operating Cash Flow | 9.96B | 11.49B | 8.47B | 9.72B | 9.26B | 10.50B | 9.15B | 11.30B | 11.18B | 10.35B | 9.08B | 8.55B |
| Free Cash Flow | 8.10B | 10.39B | 7.36B | 8.79B | 8.38B | 9.89B | 8.53B | 10.56B | 10.51B | 9.52B | 8.43B | 7.55B |
| FCF per Share | 15.06 | 19.21 | 13.76 | 16.33 | 14.70 | 16.88 | 14.10 | 15.97 | 14.38 | 12.72 | 11.12 | 9.95 |
| Book Value | 8.66B | 5.88B | 6.23B | 3.66B | 6.70B | 9.41B | 9.67B | 12.50B | 25.24B | 29.88B | 28.08B | 25.78B |
| Cash & ST Investments | 9.13B | 11.97B | 10.94B | 9.30B | 8.04B | 10.65B | 8.91B | 29.30B | 41.68B | 38.09B | 31.38B | 27.03B |
| ROC Equity | 0.89 | 0.70 | 1.08 | 1.79 | 0.88 | 0.77 | 0.81 | 0.67 | 0.08 | 0.26 | 0.25 | 0.20 |